youtube_live
Q3 2026 earnings • in 2 days
See detailschevron_right
NVAX:NASDAQ
Novavax Inc
$9.53
arrow_downward
-5.46%(-0.55) 1D
$9.71
arrow_upward
+1.92% (+0.18)bedtimeAfter hours
Closed: Nov 2, 4:00:01 PM GMT-5 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for NVAX...
Open
$10.10
High
$10.38
Low
$9.48
Mkt. cap
1.57B
Avg. vol.
7.69M
Volume
4.09M
52-wk high
$13.38
52-wk low
$6.20
EPS
-$1.52
Beta
2.44
Shares outstanding
164.95M
No. of employees
749
Open
$10.10
High
$10.38
Low
$9.48
Mkt. cap
1.57B
Avg. vol.
7.69M
Volume
4.09M
52-wk high
$13.38
52-wk low
$6.20
EPS
-$1.52
Beta
2.44
Shares outstanding
164.95M
No. of employees
749
News stories
From web sources and news partners
investingLive
·
6 minutes ago
Nasdaq’s worst month since March 2025 puts returns on AI spending in focus, says BlackRock
Foreign Policy Journal
·
52 minutes ago
Applied Digital's (NASDAQ: APLD) Interest Bill Surpasses Rent Revenue As 800 MW Financing Gap Rattles AI Infrastructure Sector
investingLive
·
1 hour ago
JPMorgan’s four midterm scenarios: S&P 500 seen moving between -0.25% and +1.25%
Bloomberg.com
·
1 hour ago
Nasdaq Slide Clouds Asian Open, Oil Falls on Iran: Markets Wrap
Profile
Novavax, Inc., based in Gaithersburg, Maryland, develops vaccines to counter infectious diseases. The company developed the Novavax COVID-19 vaccine, now commercialized by Sanofi. The company also develops vaccines for influenza, respiratory syncytial virus, avian flu, shingles, Clostridioides difficile, and malaria.
Novavax develops proprietary immune-stimulating saponin-based immunologic adjuvants at a wholly owned Swedish subsidiary, Novavax AB. One of these, Matrix-M, is used in the Novavax COVID-19 vaccine. Wikipedia
About Novavax Inc
CEOJohn C. Jacobs
Employees749
Founded1987
HeadquartersGaithersburg, Maryland, United States
SectorBiotechnology
Websitenovavax.com